Graduate Studies Faculty
Thimmappa S. Anekonda, Ph.D.
Preceptor RotationsDr. Anekonda has not indicated availability for preceptor rotations at this time.
Faculty MentorshipDr. Anekonda has not indicated availability as a mentor at this time.
Basic & Translational Research; Neuroprotection; Alzheimer’s Disease; Brain Aging
Ph.D. University of California at Berkeley, 1992.
I am interested in investigating the mechanisms of neuroprotection by herbal and non-herbal drugs against the pathways leading to age-related disorders. More specifically, I am interested in understanding the molecular pathways of Alzheimer’s disease (AD), identifying effective and safe drugs for its treatment, and evaluating these drugs for their translational potential by utilizing in vitro and animal models for AD.
One aspect of my research constitutes understanding the molecular effects of calorie restriction mimetics (CRMs). Phytochemicals such as resveratrol and phytic acid can biochemically mimic the effects of calorie restriction (CR). Both CR and CRMs affect a common pool of pathways that are implicated in an organism’s survival and longevity. Specifically, two biochemical pathways have shown much promise: (1) Anti-aging, sirtuin 1 protein in mammals, and (2) Autophagy, a cellular housekeeping pathway that modulates mitochondrial functions. While sirtuin proteins are implicated in organismal longevity, up-regulation of autophagy is essential for neuroprotection and survival. Emphasis in the AD literature addressing these pathways with CRMs is limited and only recent literature provides some preliminary insights. Investigations pertaining to mechanisms of anti-aging and autophagy and CRMs constitute an important aspect of my long-term research goal.
Anekonda TS, Reddy PH (2005) Can plants provide a new generation of drugs for treating Alzheimer’s disease? Brain Research Reviews 50:361-376.
Anekonda TS, Reddy PH (2006) Neuronal protection by sirtuins in Alzheimer’s disease. Journal of Neurochemistry, 96:305-313.
Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics. 5:1437-1449.
Anekonda TS(2006)Resveratrol—A boon for treating Alzheimer’s disease? Brain Research Reviews, 52:316-326.
Anekonda TS,Landon K, Weleber RG, Adamus G (2006) Examining pathogenecity of anti-enolase antibodies in paraneoplastic and autoimmune retinopathy. J. Neuroimmunology, 178:60.
Magrys A, Anekonda TS, Ren G, Adamus G (2007)The role of anti-alpha-enolase antibodies in pathogengecity of autoimmune-mediated retinopathy. J. Clinical Immunology. 27:181-192.
Anekonda TS, Adamus G (2008) Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70. BMC Research Notes. 1:122.
Anekonda TS(2009)The benefits of calorie restriction and calorie restriction mimetics as related to the eye. Open Longevity Journal, 3:28-37.
Pervaiz S, Holme AL, Aggarwal BB, Anekonda TS, Baur JA, Gojkovic-Bukarica L, Ragione FD, Kim AL, Pirola L, Saiko P (2009) Resveratrol: its biologic targets and functional activity. Antioxidant & Redox Signaling, 11:2851-2897.
Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL (2010) L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer’s disease. Submitted.